GSK Pharma Share Price Jumps 18.73% After Q3 FY25 Net Profit Surges to ₹308.1 crore

On Monday, February 17, 2025, GlaxoSmithKline Pharmaceuticals (GSK Pharma) share price surged by 18.73%, reaching ₹2395.75, following the company’s strong financial results for Q3 FY25. The pharmaceutical giant delivered a strong performance across its key product portfolios, with notable increases in both profit and revenue.

GSK Pharma Q3 FY25 Performance

For Q3 FY25, GSK Pharma reported a 34.7% year-on-year increase in net profit before exceptional items and tax, amounting to ₹308.1 crore, up from ₹228.7 crore in the same period last year.

Revenue also saw a significant 17.9% growth, rising to ₹949.4 crore, compared to ₹805.3 crore in Q3 FY24. This growth reflects sustained demand for the company’s core brands, which continued to perform well in the market.

EBITDA and Margin Expansion

The company’s EBITDA (earnings before interest, tax, depreciation, and amortisation) rose by 33.8%, reaching ₹291.9 crore, up from ₹218.1 crore in Q3 FY24. The EBITDA margin also saw a notable expansion, increasing to 30.7% from 27.1% in the same period last year, indicating improved operational efficiency and profitability.

Key Segment Highlights

• General Medicines Portfolio 

GSK Pharma’s flagship brands, including Augmentin, Ceftum, and T-Bact, maintained strong market positions, further solidifying their leadership in the sector.

• Respiratory Portfolio 

The company’s innovative respiratory portfolio, driven by Nucala and Trelegy, continued to grow strongly, enhancing patient access to treatment across India.

• Vaccines Business

GSK Pharma maintained its leadership in the self-pay private market for paediatric vaccines. The adult vaccines segment also saw strong growth, with the Herpes Zoster Vaccine, Shingrix, driving adoption and expanding adult immunisation efforts in India.

Management’s Confidence in Growth

Bhushan Akshikar, Managing Director of GlaxoSmithKline Pharmaceuticals, expressed confidence in the company’s future growth. “Our strong third-quarter results reflect our unwavering commitment to delivering innovative healthcare solutions to patients across India,” Akshikar stated.

He added that the company’s focus on core brands, coupled with accelerated digital transformation and innovative go-to-market strategies, continues to enhance its market presence while ensuring broader access to vital medicines and vaccines.

With the solid performance in Q3 FY25, GSK Pharma is positioned for sustained growth as it continues to strengthen its leadership in the Indian pharmaceutical market.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.